Press release
Janus kinase (JAK) Inhibitors Competitive Landscape Report 2024
DelveInsight's, "Janus kinase inhibitors Competitive landscape 2024" report provides comprehensive insights about 40+ Janus kinase Inhibitors Companies and 45+ drugs in Janus kinase inhibitors Competitive landscape. It covers the Janus kinase Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Key Takeaways from the Janus kinase Inhibitors Report
• DelveInsight's Janus kinase Inhibitors report depicts a robust space with 40+ Janus kinase Inhibitors companies working to develop 45+ pipeline therapies for Janus kinase Inhibitors treatment.
• The leading Janus kinase Inhibitors Companies working in the market include Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, and others.
• Promising Janus kinase Inhibitors Therapies in the various stages of development include KPL-404, Baricitinib, Ruxolitinib, GSK3196165 (Otilimab), Sarilumab, csDMARDs, AZD4205, TD-0903, TL-895, and others.
Request a sample and discover the recent advances in Janus kinase Inhibitors Drugs @ Janus kinase Inhibitors Competitive Landscape Report- https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Janus kinase Inhibitors report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Janus kinase Inhibitors report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Janus kinase Inhibitors Overview
Janus kinase (JAK) inhibitors are small molecules approximately 400 Da that could be administrated as oral medicines. JAKs are phosphotransferases that bind to the intracellular domains of cytokine receptors and transmit signals to activate immune responses. The family of cytokines that signal via JAKs includes many interleukins, interferons, colony stimulating factors and hormone like cytokines (such as erythropoietin).
Find out more about Janus kinase Inhibitors Analytical Perspective: In-depth Commercial Assessment @ Janus kinase Inhibitors Collaboration Analysis by Companies- https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Janus kinase Inhibitors Companies and Therapies
• Eli Lilly and Company: OLUMIANT
• AbbVie: RINVOQ
• Galapagos: Filgotinib
• Incyte: Povorcitinib
• MaxiNovel Pharmaceuticals: MAX-40279/MAX-40070
Janus kinase Inhibitors Competitive Landscape: Analytical Perspective
The Janus kinase Inhibitors report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
JAK Inhibitors Report Assessment
• Janus kinase Inhibitors Company Analysis
• Janus kinase Inhibitors Therapeutic Assessment
• Janus kinase Inhibitors Pipeline Assessment
• Inactive drugs assessment
• Janus kinase Inhibitors Unmet Needs
Learn more about the emerging Janus kinase Inhibitors Competitive Landscape @ Janus kinase Inhibitors Market Drivers and Barriers, Unmet Needs- https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Janus Kinase Inhibitors Report
• Coverage- Global
• Janus kinase Inhibitors Companies- Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, and others.
• Janus kinase Inhibitors Therapies- KPL-404, Baricitinib, Ruxolitinib, GSK3196165 (Otilimab), Sarilumab, csDMARDs, AZD4205, TD-0903, TL-895, and others.
• Janus kinase Inhibitors Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type
Dive deep into rich insights for new drugs for Janus kinase Inhibitors Product Developmental Activities, Visit @ Janus kinase Inhibitors Research and Development Activities- https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. JAK inhibitors: Overview
4. JAK inhibitors -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. JAK inhibitors: Company and Product Profiles (Marketed Therapies)
8. Eli Lilly and Company
9. OLUMIANT
10. JAK inhibitors: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Galapagos
13. Filgotinib
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. MaxiNovel Pharmaceuticals
17. MAX-40279
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. MaxiNovel Pharmaceuticals
21. MAX-40070
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. JAK inhibitors- Unmet needs
29. JAK inhibitors - Market drivers and barriers
30. Appendix
For further information on the Janus kinase Inhibitors Report @ Janus kinase Inhibitors Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Top Selling Market Research Reports in 2024
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
pigment epithelial detachment market- https://www.delveinsight.com/report-store/pigment-epithelial-detachment-market
Neuroendocrine Tumor Market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market
medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
keloid market- https://www.delveinsight.com/report-store/keloid-market
mouth neoplasms market- https://www.delveinsight.com/report-store/mouth-neoplasms-market
urinary retention market- https://www.delveinsight.com/report-store/urinary-retention-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
urea cycle disorders market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
intraocular lens market- https://www.delveinsight.com/report-store/intraocular-lens-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
embolotherapy market- https://www.delveinsight.com/report-store/embolotherapy-market
skin neoplasm market- https://www.delveinsight.com/report-store/skin-neoplasms-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
wilms tumor market- https://www.delveinsight.com/report-store/wilms-tumor-market
Rhabdomyosarcoma market- https://www.delveinsight.com/report-store/rhabdomyosarcoma-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Janus kinase (JAK) Inhibitors Competitive Landscape Report 2024 here
News-ID: 3711031 • Views: …
More Releases from DelveInsight Business Research LLP

Sjogren's Syndrome Pipeline Appears Robust With 15+ Key Pharma Companies Activel …
DelveInsight's, "Sjogren's syndrome Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Sjogren's syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Sjogren's Syndrome Research. Learn more about…

MELAS Syndrome Pipeline Appears Robust With 4+ Key Pharma Companies Actively Wor …
DelveInsight's "MELAS Syndrome Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in MELAS Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in MELAS Syndrome Research. Learn more about…

Autism Spectrum Disorder Pipeline Appears Robust With 18+ Key Pharma Companies A …
DelveInsight's, "Autism Spectrum Disorder Pipeline Insight, 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Autism Spectrum Disorder pipeline landscape. It covers the Autism Spectrum Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, clinical stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in…

Familial Adenomatous Polyposis Pipeline Appears Robust With 4+ Key Pharma Compan …
"DelveInsight's, "Familial adenomatous polyposis Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Familial adenomatous polyposis pipeline landscape. It covers the Familial Adenomatous Polyposis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Familial Adenomatous Polyposis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Janus
Janus Kinase Inhibitor Market Surges With Breakthroughs in Autoimmune Disease Tr …
Janus Kinase Inhibitor Market Overview
The Janus Kinase Inhibitor Market is forecasted to grow from USD 5.7 billion in 2025 to USD 10.8 billion by 2032, at a CAGR of 9.5% during the forecast period (2025 - 2032).
The latest report (2025-2032) on the Janus Kinase Inhibitor Market by Coherent Market Insights offers an in-depth analysis of evolving trends, key drivers, regulatory updates, and competitive intelligence. It provides data on market size,…
Janus Kinases Jaks Inhibitor Drug Market Size, Growth & Forecast 2025-2034
The Janus Kinase (JAK) Inhibitors Market Is Set To Grow At An Estimated CAGR Of 10.3% From 2025 To 2034, Rising From $11 Billion In 2024 To $30 Billion By 2034.
On April 15, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Janus Kinases Jaks Inhibitor Drug market goods. The market study excludes key regions that…
Leading Growth Driver in the Janus Kinase (JAK) Inhibitors Market in 2025: Surgi …
Which drivers are expected to have the greatest impact on the over the janus kinase (jak) inhibitors market's growth?
The escalating occurrences of autoimmune disorders are anticipated to stimulate the expansion of the Janus kinase (JAK) inhibitors market. These disorders involve a broad spectrum of abnormalities within the immune system where it erroneously attacks and destroys healthy cells, tissues, and organs. The therapeutic benefits of Janus Kinase (JAK) inhibitors for autoimmune…
Janus Kinase (JAK) Inhibitor Pipeline Therapeutics Assessment Report 2024 (Updat …
DelveInsight's, "Janus Kinase Inhibitor Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Janus Kinase…
Janus Kinase (JAK) Inhibitors Market Competitor Analysis, Growth, Insights, Tren …
"The Business Research Company recently released a comprehensive report on the Global Janus Kinase (JAK) Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
Insights into Janus Kinase (JAK) Inhibitors Market: Global Trends and Analysis
The janus kinase (jak) inhibitors market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $20.41 billion in 2024 at a compound annual growth rate (CAGR) of 18.1%. The growth in the historic period can be attributed to recognition of the role of jak-stat signaling pathway in diseases, increased prevalence of autoimmune disorders, unmet medical needs in rheumatology and dermatology, development…